Evidence map›Paper›PMID 28155077›Full record

ArticlePharmaceutical research2017

In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status.

Benjamin Guiastrennec, Erik Söderlind, Sara Richardson, Alexandra Peric, Martin Bergstrand

Abstract read
In one paragraph

Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Benjamin GuiastrennecPharmacometrics Group, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden.
Erik SöderlindPharmaceutical Technology and Development, AstraZeneca, Gothenburg, Sweden.
Sara RichardsonAdvanced Drug Delivery, Pharmaceutical Sciences, Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden.
Alexandra PericDrug Metabolism and Pharmacokinetics, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden.
Martin BergstrandPharmacometrics Group, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden. martin.bergstrand@farmbio.uu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo develop a model linking in vitro and in vivo erosion of extended release tablets under fasting and postprandial status.

methodsA nonlinear mixed-effects model was developed from the in vitro erosion profiles of four hydroxypropyl methylcellulose (HPMC) matrix tablets studied under a range of experimental conditions. The model was used to predict in vivo erosion of the HPMC matrix tablets in different locations of the gastrointestinal tract, determined by magnetic marker monitoring. In each gastrointestinal segment the pH was set to physiological values and mechanical stress was estimated in USP2 apparatus rotation speed equivalent.

resultsErosion was best described by a Michaelis-Menten type model. The maximal HPMC release rate (V

conclusionsThe in silico model accurately predicted the erosion profiles of HPMC matrix tablets under fasting and postprandial status and can be used to facilitate future development of extended release tablets.

Indexed as

AdultCalcium PhosphatesChemistry, PharmaceuticalColonComputer SimulationDelayed-Action PreparationsFastingFerric CompoundsFumaratesGastric MucosaGastrointestinal TractHumansHydrogen-Ion ConcentrationHypromellose DerivativesIntestine, SmallMalecalcium phosphate, dibasic, anhydrousCalcium PhosphatesDelayed-Action PreparationsFerric Compoundsferric oxideFumaratesHypromellose Derivativessodium stearyl fumarateTabletsfood effecthydroxypropyl methylcellulosein vitro in vivo correlationmagnetic marker monitoringNONMEM

Identifiers

PMID28155077
PMCPMC5336534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.